{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:19:26Z","timestamp":1790731166662,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier","isbn-type":[{"value":"9780443235917","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.05.001","type":"book-chapter","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T19:09:32Z","timestamp":1720033772000},"page":"11-27","source":"Crossref","is-referenced-by-count":5,"title":["Cannabidiol: Pharmacodynamics and pharmacokinetic in the context of neuropsychiatric disorders"],"prefix":"10.1016","member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2024.05.001_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"10","key":"10.1016\/bs.irn.2024.05.001_bib2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3390\/nu14102152","article-title":"Cannabidiol and cannabidiol metabolites: Pharmacokinetics, interaction with food, and influence on liver function","volume":"14","author":"Abbotts","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of Cannabidiol, a Product Isolated from the Marihuana Extract ofMinnesota Wild Hemp. I","volume":"62","author":"Adams","year":"1940","journal-title":"Journal\u00a0of the American Chemical Society"},{"key":"10.1016\/bs.irn.2024.05.001_bib4","unstructured":"Anis S. (2021). Effect of medical cannabis for non-motor symptoms of Parkinson\u2019s disease. Identifier: NCT05106504. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05106504."},{"issue":"5","key":"10.1016\/bs.irn.2024.05.001_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1021\/acs.molpharmaceut.8b01344","article-title":"Cannabidiol enhances the passage of lipid nanocapsules across the blood-brain barrier both in vitro and in vivo","volume":"16","author":"Aparicio-Blanco","year":"2019","journal-title":"Molecular Pharmaceutics"},{"issue":"4","key":"10.1016\/bs.irn.2024.05.001_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/ph16040487","article-title":"Cannabidiol-loaded nanocarriers and their therapeutic applications","volume":"16","author":"Assadpour","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antiox9010021","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"10.1016\/bs.irn.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cpdd.408","article-title":"Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology","volume":"7","author":"Atsmon","year":"2018","journal-title":"Clinical pharmacology in drug development"},{"issue":"6","key":"10.1016\/bs.irn.2024.05.001_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2024.05.001_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Current Drug Safety"},{"issue":"4","key":"10.1016\/bs.irn.2024.05.001_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","article-title":"Cannabidiol: Pharmacology and therapeutic targets","volume":"238","author":"Britch","year":"2021","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/bs.irn.2024.05.001_bib13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/bs.irn.2024.05.001_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.05.001_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacological Research: the Official Journal of the Italian Pharmacological Society"},{"issue":"2","key":"10.1016\/bs.irn.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.pnpbp.2009.08.017","article-title":"Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids","volume":"33","author":"Campos","year":"2009","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"1607","key":"10.1016\/bs.irn.2024.05.001_bib18","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00402387","article-title":"Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa","volume":"18","author":"Carlini","year":"1970","journal-title":"Psychopharmacologia"},{"issue":"24","key":"10.1016\/bs.irn.2024.05.001_bib20","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1002\/smll.201000418","article-title":"Small upconverting fluorescent nanoparticles for biomedical applications","volume":"6","author":"Chatterjee","year":"2010","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"issue":"10","key":"10.1016\/bs.irn.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/nu14102101","article-title":"Cannabidiol (CBD) dosing: Plasma pharmacokinetics and effects on accumulation in skeletal muscle, liver and adipose tissue","volume":"14","author":"Child","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1590\/1516-4446-2020-1684","article-title":"Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: Pharmaceutical vehicle matters","volume":"44","author":"Crippa","year":"2022","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"7","key":"10.1016\/bs.irn.2024.05.001_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.05.001_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/bs.irn.2024.05.001_bib25","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.xphs.2021.08.012","article-title":"Improved bioavailability with dry powder cannabidiol inhalation: A phase 1 clinical study","volume":"110","author":"Devinsky","year":"2021","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"20","key":"10.1016\/bs.irn.2024.05.001_bib26","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.05.001_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-57369-0_3","article-title":"Neuropharmacological effects of the main phytocannabinoids: A narrative review","volume":"1264","author":"Dos Santos","year":"2021","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"12","key":"10.1016\/bs.irn.2024.05.001_bib28","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/02698811221125440","article-title":"Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze","volume":"36","author":"Fabris","year":"2022","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1016\/bs.irn.2024.05.001_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.05.001_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.euroneuro.2013.10.012","article-title":"Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and previous stressful experience","volume":"24","author":"Foga\u00e7a","year":"2014","journal-title":"European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.05.001_bib31","first-page":"l1141","article-title":"Medicinal use of cannabis based products and cannabinoids","volume":"365","author":"Freeman","year":"2019","journal-title":"BMJ (Clinical Research ed.)"},{"key":"10.1016\/bs.irn.2024.05.001_bib32","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review","volume":"107","author":"Freeman","year":"2019","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: Importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2024.05.001_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"18","key":"10.1016\/bs.irn.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.3390\/molecules27186070","article-title":"Promising nanocarriers to enhance solubility and bioavailability of cannabidiol for a plethora of therapeutic opportunities","volume":"27","author":"Grifoni","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/bs.irn.2024.05.001_bib36","unstructured":"Gruber S. (2021, January \u2013 2024, September). Cannabidiol solution for the treatment of behavioral symptoms in older adults with Alzheimer\u2019s dementia (CBD). Identifier NCT04075435. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04075435."},{"issue":"14","key":"10.1016\/bs.irn.2024.05.001_bib37","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","article-title":"Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants","volume":"95","author":"Hampson","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2024.05.001_bib38","unstructured":"Jazz Pharmaceuticals (2001, May\u20132002, July). An investigation of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in multiple sclerosis patients. Identifier NCT01610700. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01610700."},{"issue":"10","key":"10.1016\/bs.irn.2024.05.001_bib39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.2042-7158.1972.tb08897.x","article-title":"The content of (-) 9 -trans-tetrahydrocannabinol (9-THC) does not explain all biological activity of some Brazilian marihuana samples","volume":"24","author":"Karniol","year":"1972","journal-title":"The Journal of Pharmacy and Pharmacology"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2024.05.001_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiology of Disease"},{"issue":"3","key":"10.1016\/bs.irn.2024.05.001_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"Journal of Drug Targeting"},{"issue":"4","key":"10.1016\/bs.irn.2024.05.001_bib43","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiological Reviews"},{"key":"10.1016\/bs.irn.2024.05.001_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: Role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2024.05.001_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linhares","year":"2019","journal-title":"Brazilian Journal of Psychiatry [Internet]"},{"issue":"32","key":"10.1016\/bs.irn.2024.05.001_bib46","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.2174\/138161212802884780","article-title":"Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers","volume":"18","author":"Martin-Santos","year":"2012","journal-title":"Current Pharmaceutical Design"},{"issue":"12","key":"10.1016\/bs.irn.2024.05.001_bib47","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"The structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"issue":"9","key":"10.1016\/bs.irn.2024.05.001_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/ph13090219","article-title":"Towards better delivery of cannabidiol (CBD)","volume":"13","author":"Millar","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/bs.irn.2024.05.001_bib49","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.05.001_bib50","doi-asserted-by":"crossref","unstructured":"Moazen-Zadeh E., Chisholm A., Bachi K., Hurd Y.L.2023).\u00a0Pharmacokinetics of cannabidiol: A systematic review and meta-regression analysis. medRxiv [Preprint]. 2023.02.01.23285341. Update in: Cannabis Cannabinoid Res. 2023 Aug 29. https:\/\/doi.org\/10.1101\/2023.02.01.23285341 PMID: 36778355; PMCID: PMC9915832.","DOI":"10.1101\/2023.02.01.23285341"},{"issue":"6","key":"10.1016\/bs.irn.2024.05.001_bib51","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/ejn.15134","article-title":"Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.","volume":"53","author":"Mori","year":"2021","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2024.05.001_bib52","unstructured":"NYU Langone Health (2021, January\u20132024, August). Cannabidiol as a treatment for social anxiety disorder (R61). Identifier: NCT05571592. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05571592."},{"issue":"8","key":"10.1016\/bs.irn.2024.05.001_bib53","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications","volume":"34","author":"Perucca","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.irn.2024.05.001_bib54","unstructured":"Ranganathan M. (2016, January\u20132018, March). Cannabidiol treatment in patients with early psychosis (CBD). Identifier NCT02504151. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02504151."},{"issue":"4","key":"10.1016\/bs.irn.2024.05.001_bib55","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ptr.7742","article-title":"Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids","volume":"37","author":"Reddy","year":"2023","journal-title":"Phytotherapy Research: PTR"},{"issue":"8","key":"10.1016\/bs.irn.2024.05.001_bib56","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochemical research"},{"key":"10.1016\/bs.irn.2024.05.001_bib57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pnpbp.2018.06.002","article-title":"Antidepressant-like effect induced by cannabidiol is dependent on brain serotonin levels","volume":"86","author":"Sales","year":"2018","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/bs.irn.2024.05.001_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"key":"10.1016\/bs.irn.2024.05.001_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.618065","article-title":"Glial cells and their contribution to the mechanisms of action of cannabidiol in neuropsychiatric disorders","volume":"11","author":"Scarante","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.05.001_bib60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17435390.2017.1306128","article-title":"An assessment of the importance of exposure routes to the uptake and internal localisation of fluorescent nanoparticles in zebrafish (Danio rerio), using light sheet microscopy","volume":"11","author":"Skjolding","year":"2017","journal-title":"Nanotoxicology"},{"issue":"2","key":"10.1016\/bs.irn.2024.05.001_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54752","article-title":"Assessment of orally administered \u03949-tetrahydrocannabinol when coadministered with cannabidiol on \u03949-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: A randomized clinical trial","volume":"6","author":"Zamarripa","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/bs.irn.2024.05.001_bib62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"issue":"22","key":"10.1016\/bs.irn.2024.05.001_bib63","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.3390\/molecules25225294","article-title":"Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: Advantages and limitations","volume":"25","author":"Zorkina","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"3","key":"10.1016\/bs.irn.2024.05.001_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology"}],"container-title":["International Review of Neurobiology","Cannabidiol in Neurology and Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:50:28Z","timestamp":1754409028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443235917"],"references-count":64,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.05.001","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}